NeuroPace (NPCE) Surges 5.8%: Is This an Indication of Further Gains?

NeuroPace, Inc. NPCE shares ended the last trading session 5.8% higher at $14.23. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 4.2% loss over the past four weeks.NeuroPace recorded a strong price rise on investors’ optimism surrounding its impending fourth-quarter 2024 financial results, which is slated to be released on March 4, 2025, post the closing bell. The Zacks Consensus Estimate for the fourth quarter revenue suggests a growth of 19.2%. This company is expected to post quarterly loss of $0.25 per share in its upcoming report, which represents a year-over-year change of -8.7%. Revenues are expected to be $21.46 million, up 19.2% from the year-ago quarter.While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.For NeuroPace, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on NPCE going forward to see if this recent jump can turn into more strength down the road.The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>NeuroPace is part of the Zacks Medical - Instruments industry. Tandem Diabetes Care, Inc. TNDM, another stock in the same industry, closed the last trading session 1.3% higher at $32.12. TNDM has returned -9.4% in the past month.Tandem Diabetes Care's consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.21. Compared to the company's year-ago EPS, this represents a change of +22.2%. Tandem Diabetes Care currently boasts a Zacks Rank of #3 (Hold).7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report NeuroPace, Inc. (NPCE): Free Stock Analysis Report Tandem Diabetes Care, Inc. (TNDM): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks